Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

doi:10.1001/jamaoncol.2018.0775

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

JAMA oncology - 1 Sept 2018

Goss Glenwood D, Felip Enriqueta, Cobo Manuel, Lu Shun, Syrigos Konstantinos, Lee Ki Hyeong, Göker Erdem, Georgoulias Vassilis, Li Wei, Guclu Salih, Isla Dolores, Min Young Joo, Morabito Alessandro, Ardizzoni Andrea, Gadgeel Shirish M, Fülöp Andrea, Bühnemann Claudia, Gibson Neil, Krämer Nicole, Solca Flavio, Cseh Agnieszka, Ehrnrooth Eva, Soria Jean-Charles

Abstract excerpt

Importance: Treatment choice for lung squamous cell carcinoma could be aided by identifying predictive biomarkers. Objective: To assess whether patient outcomes in the LUX-Lung 8 trial were associated with ERBB gene family member aberrations in tumor specimens. Design, Setting, and Participants: Ad hoc secondary analysis of the LUX-Lung 8 trial conducted at 183 centers in 23 countries from March 30, 2012, to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Carcinoma, Squamous Cell

Share to Disease-Free Survival

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 29902295
DOI: 10.1001/jamaoncol.2018.0775
PMCID: PMC6143014

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.PMID 29902295Read ↗

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Semantic proximity Read ↗

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.Semantic proximity Read ↗

Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.Semantic proximity Read ↗

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Semantic proximity Read ↗

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.Semantic proximity Read ↗

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancerSemantic proximity Read ↗

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.Semantic proximity Read ↗

Furmonertinib Activity in NSCLC Harboring EGFR L858R and ERBB2 S310F Co-Mutations: A Case Report With Literature ReviewSemantic proximity Read ↗

Clinical and molecular characteristics, transcriptome, and drug efficacy of ERBB2 tyrosine kinase and non-tyrosine kinase mutations in non-small cell lung cancerSemantic proximity Read ↗

Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.Semantic proximity Read ↗

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.Semantic proximity Read ↗

Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.